ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
Provided By GlobeNewswire
Last update: Sep 19, 2024
LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that positive results from the company’s global Phase 3 clinical trial of izokibep in moderate-to-severe hidradenitis suppurativa (HS) patients will be shared as a late-breaking oral presentation at the 2024 European Academy of Dermatology and Venereology taking place September 25-28, 2024 in Amsterdam, Netherlands. Presentation details are as follows:
Read more at globenewswire.com2.6
+0.43 (+19.82%)
Find more stocks in the Stock Screener
SLRN Latest News and Analysis
2 days ago - ChartmillThese stocks are moving in today's pre-market sessionLet's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.
2 days ago - ChartmillWondering what's happening in today's after-hours session?The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.
